Priority Review Vouchers: Majority Of US FDA Expediting Tokens Remain Unused

With Ipsen's recent approval of palovarotene, there have now been an estimated 65 priority review vouchers issued by the US FDA since the scheme started in 2007. Only 25 vouchers have been claimed, and the PVRs do not expire and can be sold, but the price appears to have peaked in 2015. Our infographic offers details on this regulatory mechanism.